Catalent touts GLP-1 manufacturing; Telix grows radiopharma capacity; Arcturus expands in Japan: #JPM24

Catal­ent’s stock $CTLT rose to the high­est it’s been in three months on Tues­day af­ter CEO Alessan­dro Masel­li em­pha­sized the CD­MO’s big pic­ture plan to man­u­fac­ture GLP-1 drugs.

Catal­ent had a rocky 2023, and is turn­ing to GLP-1 and gene ther­a­pies as a means to boost its rev­enue for this year. “Catal­ent has a lead­ing po­si­tion as a provider of ca­pac­i­ty to man­u­fac­ture GLP-1s and this will be one of the most ex­cit­ing ar­eas over the next few years,” Masel­li said at the CD­MO’s pre­sen­ta­tion at the JP Mor­gan Health­care Con­fer­ence on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.